Clinical trials: Symptomatic Knee Osteoarthritis
Osteoarthritis
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
This was a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating intra-articular LNA043 in patients with knee osteoarthritis.
- Trial name
- ONWARDS (NCT04864392)
- Testing
- LNA043
- Where
- 75 sites in United States, Argentina and 13 more
- Volunteers
- 576 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis of Knee
Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis
This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.
- Trial name
- NCT04506463
- Testing
- MM-II dose I, MM-II dose II, MM-II dose III
- Where
- 25 sites in United States, Denmark and 1 more
- Volunteers
- 397 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Knee Osteoarthritis
Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis
The primary objective of this study is to compare a combination of hyaluronic acid and chondroitin sulfate (V0220) to Hyalgan® on pain relief in patients with symptomatic knee osteoarthritis (OA) over 24 weeks when administered…
- Trial name
- VESTA (NCT01469507)
- Testing
- Chondroitin sulfate and sodium hyaluronate, Hyaluronan
- Sponsor
- Pierre Fabre Medicament
Osteo Arthritis Knee, Arthritis
Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
The purpose of this study is to assess the ability of long-duration low-intensity therapeutic ultrasound (LITUS) to alleviate knee Osteoarthritis pain over an 8-week period.
- Trial name
- NCT05882812
- Testing
- Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ZetrOZ, Inc.
Knee Osteoarthritis
Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee
The purpose of this study is to assess whether a single injection hyaluronic acid (HA) product is not inferior to a 3 injection HA product at 24 weeks (6 months), in terms of effectiveness in reducing pain when walking in…
- Trial name
- NCT01543737
- Testing
- 3ml hyaluronic acid (DUROLANE), 2ml hyaluronic acid, (HYALGAN)
- Where
- 17 sites in France, Monaco
- Volunteers
- 290 people
- Sponsor
- Bioventus LLC
Knee Osteoarthritis
Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee
This study is designed as a double-blind, randomised, placebo-controlled, four parallel arm, dose-finding study, to be conducted in approximately 26 sites, to evaluate the efficacy, safety, tolerability, and pharmacokinetics of…
- Trial name
- ALBATROSS-3 (NCT02205814)
- Testing
- Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose
- Where
- 25 sites in United States, Czechia and 2 more
- Volunteers
- 436 people
- Sponsor
- Menarini Group
Osteoarthritis, Knee
A First-in-Human Study of XSTEM-OA in Patients With Knee Osteoarthritis
The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-OA when administered as a single intra-articular injection to patients with symptomatic knee osteoarthritis.
- Trial name
- NCT05344157
- Testing
- XSTEM-OA
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Xindu Pty Ltd
Osteoarthritis, Knee
A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS
The purpose of this study is to determine whether intra-articular (knee joint) administration of MEN16132 is effective reducing the pain from knee osteoarthritis.
- Trial name
- ALBATROSS (NCT01091116)
- Testing
- MEN16132 - 0.125 mg, MEN16132 - 0.25 mg, MEN16132 - 0.5 mg
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 423 people
- Sponsor
- Menarini Group
Osteoarthritis
A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)
Primary Objective: To evaluate the change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore (walking pain) at 26 weeks compared to the Baseline score To evaluate the safety using the incidence…
- Trial name
- NCT01586338
- Testing
- Hylan G-F 20
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Sanofi
Joint Disease
Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee Osteoarthritis
The primary objective is to compare the overall treatment effect on pain relief between icatibant and placebo. The secondary objectives are to assess the efficacy of icatibant in term of onset, extent and duration of pain relief…
- Trial name
- NCT00303056
- Testing
- HOE140 Icatibant
- Where
- 5 sites in United States, Austria and 3 more
- Volunteers
- 590 people
- Sponsor
- Sanofi
Osteoarthritis
Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee
Primary Objective: -To evaluate the efficacy of a single 6-milliliter (mL) intra-articular (IA) injection of Hylan G-F 20 measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numerical Rating Scale…
- Trial name
- C-SOUND (NCT03190369)
- Testing
- Hylan G-F 20 (GZ402662/SAR402662)
- Where
- 21 sites in China
- Volunteers
- 440 people
- Sponsor
- Genzyme, a Sanofi Company
Knee Osteoarthritis
Assessment of Efficacy of a Single Intra-articular Injection of HYALUBRIX 60 in Knee Osteoarthritis
The purpose of this study is to evaluate the effect of one single intra-articular (IA) injection of HYALUBRIX 60® plus physical exercise program (PEP) in terms of pain reduction, compared to PEP alone, in patients with knee…
- Trial name
- NCT06113783
- Testing
- HYALUBRIX 60
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Knee Osteoarthritis
Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic…
- Trial name
- STRIDES-Xray (NCT03928184)
- Testing
- Lorecivivint
- Where
- 99 sites in United States
- Volunteers
- 501 people
- Sponsor
- Biosplice Therapeutics, Inc.
Osteoarthritis
A Trial of SB-061 in Osteoarthritis of the Knee
This study evaluates a novel agent, SB-061, for the treatment of osteoarthritis of the knee. Half of the patients will receive the agent via intra-articular injection and half will receive a placebo injection.
- Trial name
- MODIFY-OA (NCT02802709)
- Testing
- SB-061
- Where
- 2 sites in Estonia
- Volunteers
- 90 people
- Sponsor
- Symic OA Co.
Osteoarthritis, Osteoarthritis, Knee
A Study to Evaluate the Efficacy, Safety and Tolerability of EVI-01 Intra-Articular Injection in Osteoarthritis of the Knee
Objective: Identifying the dose of EVI-01 with the best clinical response, balancing the efficacy, safety, and tolerability of the investigational product.
- Trial name
- NCT05337540
- Testing
- EVI-01, Active comparator Synvisc-One
- Where
- 2 sites in Brazil
- Volunteers
- 120 people
- Sponsor
- Aptissen SA
Osteoarthritis, Osteoarthritis, Knee
Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
Osteoarthritis (OA) of the knee is the most frequent cause of knee pain after the age of 50 years. OA is a joint disease characterised by articular cartilage loss associated with structural changes in the cartilage and adjacent…
- Trial name
- DISSCO (NCT02688400)
- Testing
- Diacerein, Celecoxib
- Where
- 22 sites in Austria, Belgium and 3 more
- Volunteers
- 380 people
- Sponsor
- TRB Chemedica International SA
Osteoarthritis, Knee
Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
This is a multi-center, randomized, double-blind, parallel group, placebo controlled trial to compare the safety and effectiveness of a single injection of Cingal® to a single injection of Triamcinolone Hexacetonide (TH) to…
- Trial name
- NCT04231318
- Testing
- Cingal, Triamcinolone Hexacetonide (TH)
- Where
- 26 sites in United States
- Volunteers
- 231 people
- Sponsor
- Anika Therapeutics, Inc.
Knee Osteoarthritis
sAfety PerfoRmance chitOsan osteOarthritis ViscosupplEmentation
KIO014 is an innovative chitosan-based biomaterial intended for synovial fluid viscosupplementation indicated for the symptomatic treatment of knee osteoarthritis (OA).
- Trial name
- APROOVE (NCT03679208)
- Testing
- Investigational device coded KIO014, Durolane(r) as control device
- Volunteers
- 100 people
- Sponsor
- Kiomed Pharma
Knee Osteoarthritis
CRx-102 Osteoarthritis Multicenter Evaluation Trial
CRx-102 is a synergistic combination drug candidate containing the cardiovascular drug dipyridamole and a very low dose of the glucocorticoid prednisolone.
- Trial name
- COMET-1 (NCT00521989)
- Testing
- CRx-102 (2.7/90), Prednisolone, CRx-102 (2.7/180)
- Where
- 58 sites in United States, Canada
- Volunteers
- 279 people
- Sponsor
- Zalicus
Osteoarthritis, Knee
Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
Evaluation of safety, tolerability and efficacy of a single intra-articular (IA) injection of PTP-001, an allogeneic placental tissue particulate, in individuals with knee osteoarthritis (OA).
- Trial name
- NCT05100225
- Testing
- PTP-001
- Where
- 14 sites in Australia, Canada and 1 more
- Volunteers
- 210 people
- Sponsor
- Bioventus LLC